Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 45

Exclusive: Start-up FutureHouse debuts powerful AI ‘reasoning model’ for science

As artificial intelligence (AI) tools shake up the scientific workflow, Sam Rodriques dreams of a more systemic transformation. His start-up company, FutureHouse in San Francisco, California, aims to build an ‘AI scientist’ that can command the entire research pipeline, from hypothesis generation to paper production.

Today, his team took a step in that direction, releasing what it calls the first true ‘reasoning model’ specifically designed for scientific tasks. The model, called ether0, is a large language model (LLM) that’s purpose-built for chemistry, which it learnt simply by taking a test of around 500,000 questions. Following instructions in plain English, ether0 can spit out formulae for drug-like molecules that satisfy a range of criteria.

Potential new treatment for Alzheimer’s disease, other neurodegenerative conditions

Drug developed by Case Western Reserve University researchers found to protect ‘guardian of the brain’ Worldwide, more than 55 million people suffer from dementia caused by Alzheimer’s Disease (AD) and other conditions that destroy cells in the brain and nervous system. While there is no treatment to control or manage these neurodegenerative conditions, investigators at Case Western Reserve University, University Hospitals and the Louis Stokes Cleveland VA Medical Center have identified a new and promising drug to treat AD. The […]

Retinal Prosthesis Grants Artificial Vision to Blind Mice and Enables

A groundbreaking advancement in the field of vision restoration has recently emerged from the intersection of nanotechnology and biomedical engineering. Researchers have developed a novel retinal prosthesis constructed from tellurium nanowires, which has demonstrated remarkable efficacy in restoring vision to blind animal models. This innovative approach not only aims to restore basic visual function but also enhances the eye’s capability to detect near-infrared light, a development that holds promising implications for future ocular therapies.

The retina, a thin layer of tissue at the back of the eye, plays a crucial role in converting light into the electrical signals sent to the brain. In degenerative conditions affecting the retina, such as retinitis pigmentosa or age-related macular degeneration, this process is severely disrupted, ultimately leading to blindness. Traditional treatments have struggled with limitations such as electrical interference and insufficient long-term impacts. However, the introduction of a retinal prosthesis made from tellurium offers a fresh perspective on restoring vision.

Tellurium is a unique element known for its semiconductor properties, making it an excellent choice for developing nanostructured devices. The researchers carefully engineered tellurium nanowires and then integrated them into a three-dimensional lattice framework. This novel architecture facilitates easy implantation into the retina while enabling efficient conversion of both visible and near-infrared light into electrical impulses. By adopting this approach, the researchers ensured that the prosthesis would function effectively in various lighting conditions, a significant consideration for practical application in real-world scenarios.

Do neurons transmit light?

“Scientists have shown that there is ultra-weak photon emission in the brain, but no one understands why the light is there.”

If light is at play and scientists can understand why, it could have major implications for medically treating brain diseases and drastically change the way physicians heal the brain. But measuring optical transport between neurons would be no easy task.

Our brain and nerves rely on incredibly fast electrical signals to communicate, a process long understood to involve tiny bursts of electricity called action potentials that travel along nerve fibers. But scientists are now exploring whether something else might also be part of this picture: light.

Yes—light, or more specifically, photons. Some researchers have suggested that nerves might not only use electrical impulses but could also send signals using photons, the same particles that make up visible light. This idea is based on the possibility that the fatty coating around nerves, called the myelin sheath, could act like an optical fiber—just like the cables used to carry internet signals using light.

In earlier work, the researchers behind this new study proposed that light might actually be generated in specific parts of the nerve called nodes of Ranvier, which are tiny gaps in the myelin sheath that help boost the electrical signal. Now, they’ve gone a step further: using a special photographic technique involving silver ions, they’ve found physical evidence of photons being emitted from these nodes during nerve activity.

Their experiments suggest that, alongside the familiar electrical signals, nerves might also be emitting light when they fire—shining a new light, literally and figuratively, on how our nervous system might work.

Continue reading “Do neurons transmit light?” | >

AI-designed drug shows early promise for lung fibrosis patients in clinical trial

Researchers report that rentosertib, an AI-discovered TNIK inhibitor, showed promising safety and potential to improve lung function in patients with idiopathic pulmonary fibrosis in a 12-week phase 2a clinical trial. The highest dose group demonstrated a trend toward increased forced vital capacity, especially among patients not receiving standard antifibrotic therapy, supporting further clinical investigation.

How our bones are repaired by skeletal stem cells: Scientist discover four major subtypes

Whether you are a competitive athlete or an older adult, strong bones are essential—not only for movement, but also for overall health. Now, a new study has shed new light on how our bones are maintained and repaired by stem cells—and how that process is disrupted with age and in situations of poor healing. The findings could open doors to therapies that speed recovery from injuries, improve bone health, and boost performance longevity.

“Stem cells are the source of all new formation, and so work like this is really the foundation of developing new treatments for conditions of poor skeletal health and delayed or impaired fracture regeneration,” said Thomas Ambrosi, who led this study while he was a postdoctoral fellow in Charles Chan’s laboratory at Stanford University and later in his current position as an assistant professor of Orthopedic Surgery at UC Davis. The study was published in Cell Stem Cell.

“This work exemplifies the mission of the Wu Tsai Human Performance Alliance to advance science that helps people stay healthy, recover faster, and achieve peak performance,” said Michael Longaker, MD, a senior author on the study, a professor in the School of Medicine at Stanford University, and a member of the Wu Tsai Human Performance Alliance at Stanford.

WVU student discovers long-awaited mystery fungus sought by LSD’s inventor

Making a discovery with the potential for innovative applications in pharmaceutical development, a West Virginia University microbiology student has found a long sought-after fungus that produces effects similar to the semisynthetic drug LSD, which is used to treat conditions like depression, post-traumatic stress disorder and addiction.

Corinne Hazel, of Delaware, Ohio, an environmental microbiology major and Goldwater Scholar, discovered the new species of fungus growing in morning glory plants and named it Periglandula clandestina.

Hazel made the discovery while working in the lab with Daniel Panaccione, Davis-Michael Professor of Plant and Soil Sciences at the WVU Davis College of Agriculture and Natural Resources. She was studying how morning glories disperse protective chemicals called “ergot alkaloids” through their roots when she saw evidence of a fungus.

Balancing Midurethral Sling vs OnabotulinumtoxinA for Mixed Urinary Incontinence

Mixed urinary incontinence presents a clinical conundrum. Patients with mixed urinary incontinence report symptoms of both stress incontinence (loss of urine with exertion) and urge incontinence (loss of urine with urgency). Mixed urinary incontinence is a combination of the two that affects 37% of women older than age 65 years.1 The personal and societal costs of incontinence are significant. In women with symptoms of severe urinary incontinence, the cost of supplies, laundry, and dry cleaning range from $900 to $4000 annually.2 By 80 years of age, 20% of women will undergo surgery for stress or mixed urinary incontinence.3 Physical and behavioral therapy improves both incontinence types, and medications are standard treatment for urgency urinary incontinence. When conservative therapies fail, conventional guidance has been to treat the urgency prior to the stress component of mixed incontinence, because anti-incontinence surgical procedures can worsen urgency incontinence, and many urgency treatments are medical rather than surgical.4-7 Another strategy has been to treat whichever symptom is dominant.8

A previously published randomized trial of patients with mixed urinary incontinence compared midurethral sling plus behavioral and physical therapy vs sling alone. Findings from the Effects of Surgical Treatment Enhanced With Exercise for Mixed Urinary Incontinence (ESTEEM) trial revealed that both groups, with or without behavioral and physical therapy, reported improved urgency symptoms, findings that substantiated prior cohort studies.9-11 While the original hypothesis of ESTEEM was that treating both components of mixed urinary incontinence with behavioral and physical therapy plus sling would result in better patient outcomes, ESTEEM revealed that urgency symptoms can improve with the midurethral sling alone, challenging previously held beliefs about the impact of anti-incontinence surgeries worsening the urgency component of mixed incontinence.

In this issue of JAMA, investigators report the results of an important trial that is the next natural step in exploring how best to treat mixed urinary incontinence.12 The Treatment for Mixed Urinary Incontinence: Midurethral Sling vs Botox A (MUSA) is a randomized clinical trial of 137 patients with mixed urinary incontinence and moderate bother from both stress and urge symptoms randomized to either the midurethral sling or 100 U of onabotulinumtoxinA.12 Participants had an average number of 7 leakage episodes a day, representing patients severely affected by incontinence. Importantly, patients previously had unsuccessful conservative interventions, including medications. The investigators hypothesized that treating the urgency component of mixed urinary incontinence with onabotulinumtoxinA would result in better outcomes than focusing on the stress component with a midurethral sling.